151 related articles for article (PubMed ID: 26260387)
1. The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Takeuchi A; Nobumoto A; Tsuda M; Yokoyama A
Leukemia; 2015 Dec; 29(12):2296-306. PubMed ID: 26260387
[TBL] [Abstract][Full Text] [Related]
2. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738
[TBL] [Abstract][Full Text] [Related]
3. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
[TBL] [Abstract][Full Text] [Related]
4. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
[TBL] [Abstract][Full Text] [Related]
5. STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells.
Takeuchi A; Nishioka C; Ikezoe T; Yang J; Yokoyama A
Leuk Res; 2015 Aug; 39(8):897-905. PubMed ID: 26059451
[TBL] [Abstract][Full Text] [Related]
6. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of hyperactivated AKT1 with additional genes activated in leukemia drives hematopoietic progenitor cells to cell cycle block and apoptosis.
Tang Y; Halvarsson C; Nordigården A; Kumar K; Åhsberg J; Rörby E; Wong WM; Jönsson JI
Exp Hematol; 2015 Jul; 43(7):554-64. PubMed ID: 25931014
[TBL] [Abstract][Full Text] [Related]
8. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target.
Zhang S; Zhang Q; Shi G; Yin J
Biomed Pharmacother; 2018 Jan; 97():1189-1194. PubMed ID: 29136958
[TBL] [Abstract][Full Text] [Related]
9. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A.
Yang J; Ikezoe T; Nishioka C; Nobumoto A; Udaka K; Yokoyama A
Int J Cancer; 2013 Dec; 133(11):2706-19. PubMed ID: 23686525
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
[TBL] [Abstract][Full Text] [Related]
11. [Expression of BCL2L12 gene in de novo acute myeloid leukemia and its clinical implications].
Yu MX; Lu Y; Mu QT; Wang Q; Chen ZM; Lou JY; Jin J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct; 30(5):544-8. PubMed ID: 24078567
[TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
Li Y; Huang X; Zhang J; Li Y; Ma K
Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
14. Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo.
Nishioka C; Ikezoe T; Yokoyama A
Cancer Med; 2015 Sep; 4(9):1426-31. PubMed ID: 26139471
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia.
Thomadaki H; Floros KV; Pavlovic S; Tosic N; Gourgiotis D; Colovic M; Scorilas A
Clin Biochem; 2012 Nov; 45(16-17):1362-7. PubMed ID: 22728012
[TBL] [Abstract][Full Text] [Related]
16. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
[TBL] [Abstract][Full Text] [Related]
17. CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/β-catenin signaling pathway.
Ji H; Chen L; Xing Y; Li S; Dai J; Zhao P; Wang Y
Pediatr Res; 2019 Jun; 85(7):1024-1031. PubMed ID: 30862962
[TBL] [Abstract][Full Text] [Related]
18. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
19. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Yang MC; Loh JK; Li YY; Huang WS; Chou CH; Cheng JT; Wang YT; Lieu AS; Howng SL; Hong YR; Chou AK
Int J Oncol; 2015 Mar; 46(3):1304-16. PubMed ID: 25586056
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+ /CD38- cells and sensitizes them to antileukemia agents.
Ikezoe T; Yang J; Nishioka C; Kojima S; Takeuchi A; Phillip Koeffler H; Yokoyama A
Int J Cancer; 2011 May; 128(10):2317-25. PubMed ID: 21128225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
